These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16009844)

  • 1. Treating intraocular inflammatory disease in the 21st century.
    Nussenblatt R
    Arch Ophthalmol; 2005 Jul; 123(7):1000-1. PubMed ID: 16009844
    [No Abstract]   [Full Text] [Related]  

  • 2. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in uveitis treatment.
    Rudometkin N; Mandava N; Deane K; Olson JL
    Arch Ophthalmol; 2006 Aug; 124(8):1211; author reply 1211-2. PubMed ID: 16908832
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimizing the use of tumor necrosis factoralpha inhibitors in refractory uveitis.
    Sebastian RT; Harding SP; Bucknall RC; Pearce IA
    Arch Ophthalmol; 2006 Oct; 124(10):1505; author reply 1505-6. PubMed ID: 17030729
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologic agents in experimental autoimmune uveitis.
    Giuliari GP; Sadaka A; Hinkle DM
    Int Ophthalmol; 2014 Feb; 34(1):145-56. PubMed ID: 23494482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis.
    Demir T; Gödekmerdan A; Balbaba M; Türkçüoglu P; Ilhan F; Demir N
    Indian J Ophthalmol; 2006 Dec; 54(4):241-5. PubMed ID: 17090875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable response to high-dose infliximab for refractory childhood uveitis.
    Kahn P; Weiss M; Imundo LF; Levy DM
    Ophthalmology; 2006 May; 113(5):860-4.e2. PubMed ID: 16545455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncovering the risks of immunosuppressive therapy in patients with uveitis.
    Goldstein DA
    Arch Ophthalmol; 2009 Jun; 127(6):799-800. PubMed ID: 19506201
    [No Abstract]   [Full Text] [Related]  

  • 10. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
    Suhler EB; Smith JR; Giles TR; Lauer AK; Wertheim MS; Kurz DE; Kurz PA; Lim L; Mackensen F; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2009 Jun; 127(6):819-22. PubMed ID: 19506209
    [No Abstract]   [Full Text] [Related]  

  • 11. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
    Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab: new indication. A last resort for treating plaque psoriasis: just another TNF alpha antagonist.
    Prescrire Int; 2008 Dec; 17(98):240. PubMed ID: 19422152
    [No Abstract]   [Full Text] [Related]  

  • 13. [Monoclonal antibodies in chronic autoimmune inflammatory diseases].
    Semerano L; Boissier MC
    Med Sci (Paris); 2009 Dec; 25(12):1108-12. PubMed ID: 20035687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF inhibitors for uveitis: balancing efficacy and safety.
    Cunningham ET; Zierhut M
    Ocul Immunol Inflamm; 2010 Dec; 18(6):421-3. PubMed ID: 21091055
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of posterior noninfectious uveitis : Current situation and future developments].
    Pleyer U; Pohlmann D; Stübiger N
    Ophthalmologe; 2016 May; 113(5):380-90. PubMed ID: 27165275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutting-edge issues in autoimmune uveitis.
    Levy RA; de Andrade FA; Foeldvari I
    Clin Rev Allergy Immunol; 2011 Oct; 41(2):214-23. PubMed ID: 21913066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats.
    Oh-i K; Keino H; Goto H; Yamakawa N; Murase K; Usui Y; Kezuka T; Sakai J; Takeuchi M; Usui M
    Br J Ophthalmol; 2007 Feb; 91(2):237-42. PubMed ID: 16987901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
    Lee RW; Dick AD
    Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
    MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.